Pharmaceutical Stocks

Pharmaceutical stocks have grown tremendously as medicine advances. With diseases like Covid-19, diabetes, liver disease and other illnesses affecting more and more of the population, pharmaceutical companies are racing to find cures – further advancing medicine and driving pharma stock prices higher.

Big Pharma corporations like AstraZeneca, Merck & Co., Pfizer, and Johnson & Johnson are leading the charge against the novel coronavirus, competing with smaller biotech names — such as Moderna and Novavax. The race to find a Covid-19 vaccine has sent both pharma and biotech stocks to the moon.

Novartis Cutting 2,000 Jobs – So Much for Healthy Healthcare Stocks!

By InvestorPlace Staff
Novartis NYSE:NVS is cutting nearly 2,000 jobs in the United States. The reason? Patent expiration for its blockbuster blood pressure drug Diovan.

Merck Is Shopping for Smarts In Hep C

By Barry Cohen, Health Care Writer
The pharma giant says it's determined to be the leader in treatments for the disease -- a market that is expected to hit $20 billion by 2020.

8 Pharma Stocks in Good Health

By Louis Navellier, Editor, Growth Investor
The health care sector is a field that will continue to grow as Baby Boomers get old and retire. These eight companies will be at the center of this trend.

WebMD’s Business Model May Need Surgery

By Susan J. Aluise, Aviation, Auto & Transportation Writer
Big Pharma’s ad pullback and competition from social media have slammed the health-info site. In fact, the biggest threat to WebMD may be Facebook and Twitter.

Idenix and Achillion Jump on Takeover Talk

By Barry Cohen, Health Care Writer
Their hepatitis C drugs could be lures for Big Pharma after a rival gets a juicy offer from Bristol-Myers Squibb.

Where to Invest During the Last Stage of the Market Recovery

By Louis Navellier, Editor, Growth Investor
Add these stocks from the consumer staples, health care and utilities sectors during this final stage in the U.S. economy's recovery.

Top 5 Emerging Growth Stocks to Buy for January

By Louis Navellier, Editor, Growth Investor
The list of the top five emerging growth stocks to buy for January include tech and pharmaceutical companies -- as well as a "monster" beverage play.

Jazz Pharma’s Bullish Run Looks Tapped Out

By John Kmiecik, InvestorPlace Contributor
This is a speculative play but, if this trade idea is triggered, the stock might be able to drop to $42 in a hurry.

Dendreon Jumps 40% on Provenge Sales

By Barry Cohen, Health Care Writer
Dendreon saw its stock jump Thursday as sales of its cancer drug beat the expectations of both analysts and the company itself.

Teva’s New CEO Is Battle-Tested. Good Thing

By Barry Cohen, Health Care Writer
Drug industry vet Jeremy Levin earned his stripes making deals for Bristol-Myers Squibb, but he'll face tough going at the generic-drug maker.

Mead Johnson Bounce Followed J&J Script

By Barry Cohen, Health Care Writer
Mead Johnson's recent Enfamil scare sent many investors packing -- but those who stuck with the stock could soon be rewarded.

FDA, Insurers Demand Tests for New Drugs

By Barry Cohen, Health Care Writer
Pressure on pharmaceutical companies for evidence that their drugs work is fueling a surge in the global market for "companion diagnostics."

Acquisitions, Strong Sales Keep Pfizer Dividend Strong

By Louis Navellier, Editor, Growth Investor
Despite stagnant revenue growth, good operating margins for Pfizer (NYSE:PFE) leaves room for cash-generating dividends for investors.

Ariad Pharmaceuticals Still Might Have Upside

By Barry Cohen, Health Care Writer
Ariad Pharmaceuticals is up 120% in the past 12 months, mostly fueled on optimism over its trial leukemia treatment. But some analysts think the ceiling is higher.

Amgen CEO Says ‘I’m Leaving.’ Investors Say ‘Good Riddance’

By Barry Cohen, Health Care Writer
After a decade as CEO, the oft-maligned Kevin Sharer will step down. That's giving shareholders holiday cheer as they bid the stock up on the news.

Researcher: J&J/Pharmacyclics Drug Could Be a Game-Changer

By Barry Cohen, Health Care Writer
The experimental cancer drug Johnson & Johnson bought last week is receiving high praise, and could be "paradigm-shifting."

Covidien Follows Abbott With a Pharma Spin-Off

By Barry Cohen, Health Care Writer
Could Sanofi, Novartis or GlaxoSmithKline be next to separate pharmaceutical development into a stand-alone company?

7 Feel-Good Pharma Stocks to Buy

By Louis Navellier, Editor, Growth Investor
Medicine is something few people can afford to go without during times of recession, making these pharma companies good sources of stability.

Pfizer Delivers Early Holiday Gifts to Shareholders

By Barry Cohen, Health Care Writer
The company brings holiday cheer with its new stock repurchase program and dividend boost.
Load More